Amgen (AMGN) Price Target Lifted to $187 at Leerink Partners
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St recovers as yields ease; Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Amgen (AMGN) Price Target Raised to $195 at Jefferies
April 22, 2015 11:41 AM EDTIn a note earlier, Jefferies analyst Eun K. Yang reiterated a Buy rating and boosted his price target on Amgen (NASDAQ: AMGN) to $195.00 (from $182.00) following Q1 results.
Yang commented, "Reported ~18% higher EPS (vs. cons) on ~3% higher product sales & lower OpEx; upped FY15 EPS guidance... More
Amgen (AMGN) Tops Q1 EPS by 38c; Boosts FY15 Outlook
April 21, 2015 4:03 PM EDTAmgen (NASDAQ: AMGN) reported Q1 EPS of $2.48, $0.38 better than the analyst estimate of $2.10. Revenue for the quarter came in at $5.03 billion versus the consensus estimate of $4.91 billion.
Amgen sees FY2015 EPS of $9.35 - $9.65, versus the consensus of $9.32. Amgen sees FY2015 revenue of $20.9 - $21.3... More
